Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 – 22. Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium bromide inhalation powder)], as well as investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) and COPD.

The breadth of Boehringer Ingelheim data at ATS 2013, one of the largest gatherings of pulmonary clinicians and researchers in the world, reinforces the company's commitment to lung health and to finding solutions for physicians and patients where unmet needs exist.

Boehringer Ingelheim's abstracts in respiratory research can be accessed through the ATS website, http://conference.thoracic.org. The data will remain under embargo until the date and time that the data are presented (details below).

Tiotropium (Investigational)  
Tiotropium is being investigated to determine its efficacy and safety in treating patients with asthma and is not approved for this indication.

Nintedanib
Nintedanib is being investigated to determine its efficacy and safety in treating patients with IPF and is not approved for this indication.

Olodaterol and tiotropium + olodaterol   
Olodaterol and the combination of tiotropium plus olodaterol are being investigated to determine their efficacy and safety in treating patients with COPD and are not approved for this indication.

Tiotropium bromide inhalation powder  
Tiotropium bromide inhalation powder, which is marketed as Spiriva® HandiHaler® in the U.S. by Boehringer Ingelheim and Pfizer, Inc., is a once-daily long-acting inhaled muscarinic antagonist (LAMA) indicated for both the maintenance treatment of bronchospasm (narrowing of the airways) associated with COPD, including chronic bronchitis and emphysema, and to reduce exacerbations.

Source:

Boehringer Ingelheim Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Progress and challenges in the development of mRNA vaccines against respiratory syncytial virus